Meloxicam and rizatriptan Brand names: Symbravo

What is meloxicam and rizatriptan used for?

From the label: indications and usage

SYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use SYMBRAVO should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with SYMBRAVO, the diagnosis of migraine should be reconsidered before SYMBRAVO is administered to treat any subsequent attacks. SYMBRAVO is not indicated for the preventive treatment of migraine attacks. SYMBRAVO is not indicated for the treatment of cluster headache. […]

Conditions named in the indications of meloxicam and rizatriptan's FDA labels, with every medicine labeled for each:

• Migraine

FDA pharmacologic class: Nonsteroidal Anti-inflammatory Drug and Serotonin-1b and Serotonin-1d Receptor Agonist.

What does the patient leaflet for meloxicam and rizatriptan say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about SYMBRAVO?

SYMBRAVO contains 2 medicines: meloxicam (a nonsteroidal anti-inflammatory drug [NSAID]) and rizatriptan (a triptan). NSAIDs, including SYMBRAVO, can cause serious side effects, including: Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase: with increasing doses of NSAIDs with longer use of NSAIDs Do not take SYMBRAVO right before or after a heart surgery called a “coronary artery bypass graft (CABG).” Avoid taking SYMBRAVO after a recent heart attack unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. Stop taking SYMBRAVO and get emergency help right away if you have any of the following symptoms of a heart attack or stroke: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded weakness in one part or on side of your body slurred speech SYMBRAVO is not for people with risk factors for heart disease unless a heart exam is done and shows no problem. […]

From the patient leaflet: What should I avoid while taking SYMBRAVO?

SYMBRAVO may cause dizziness, weakness, or drowsiness. If you have these symptoms, do not drive a car, use machinery, or do anything that needs you to be alert.

From the patient leaflet: How should I store SYMBRAVO?

Store SYMBRAVO at room temperature between 68°F to 77°F (20°C to 25°C). Safely throw away medicine that is out of date or no longer needed. Keep SYMBRAVO and all medicines out of the reach of children.

Is there a generic for meloxicam and rizatriptan (Symbravo)?

No generic meloxicam and rizatriptan is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 96 patents for Symbravo tablets, the last expiring on March 10, 2045. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

What do pharmacies pay for meloxicam and rizatriptan (Symbravo)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $122.64 per Symbravo 20-10 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

What does the meloxicam and rizatriptan label say about other medicines?

The meloxicam and rizatriptan label names 13 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Check meloxicam and rizatriptan against other medicines

What do FAERS reports show for meloxicam and rizatriptan?

The FDA Adverse Event Reporting System holds 28 reports that list meloxicam and rizatriptan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 2 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

• Dizziness (named in the label)4
• Drug Ineffective (a use or a product term, not a reaction)4
• Fatigue3
• Feeling Abnormal3
• Headache (a use or a product term, not a reaction)3
• Palpitations3
• Asthenia2
• Flushing2

What else is labeled for the same conditions as meloxicam and rizatriptan?

13 other medicines are given the same way (oral) and in the same FDA class as meloxicam and rizatriptan or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Every medicine labeled for the same conditions as meloxicam and rizatriptan

What next?

Alternatives to meloxicam and rizatriptan

13 medicines for the same use

Other NSAIDs

the pharmacologic class, with prices and generics

Meloxicam and rizatriptan side effects

the label's list beside FAERS reports

Check an interaction

what two or more labels say about each other